CTSC (Cathepsin C / Dipeptidyl Peptidase I) Drug Discovery Landscape & Assay Solutions
- By admin
- 28 Jul 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CTSC drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Active) | CTSC Active Recombinant Protein (Mature Tetramer), High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified, HEK293 Expressed. | View CTSC Products |
| Mutant Panel | CTSC Disease-Associated Mutants (R272X, G249S, etc.) – Papillon-Lefèvre Syndrome variants for selectivity screening. | View CTSC Products |
| Gene Delivery | CTSC Premade ORF Lentivirus / Lentiviral Particles, Full-length ORF for stable cell lines. | View CTSC Products |
| Benchmark Ab | Anti-CTSC Antibody (Research Grade), Recombinant monoclonal for assay calibration. | View CTSC Products |
| Validator | CTSC siRNA Set (3 unique sequences), For knockdown verification and specificity controls. | View CTSC Products |
| Related Target A | Cathepsin S (CTSS) – Off-target liability within cysteine cathepsin family. | View CTSS Products |
| Related Target B | Cathepsin B (CTSB) – Lysosomal cysteine protease; critical selectivity counter-screen target. | View CTSB Products |
| Related Target C | Cathepsin L (CTSL) – Collagen degradation pathway; off-target liability for CTSC inhibitors. | View CTSL Products |
| Related Target D | Neutrophil Elastase (ELANE) – Downstream effector activated by CTSC; biomarker for pharmacodynamics. | View ELANE Products |
| Related Target E | Proteinase 3 (PRTN3) – Key effector in ANCA-associated vasculitis, downstream of CTSC. | View PRTN3 Products |
| Related Target F | DPP4 / CD26 – Surface dipeptidyl peptidase; selectivity discrimination assay essential. | View DPP4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Zymogen processing & tetrameric assembly validation | Active CTSC mature form with heavy/light chain integrity, Sequence Verified, Theoretical MW confirmed, >95% purity |
| Family selectivity (Cathepsins B/L/S/K) | Homolog Panel Available: CTSC, CTSB, CTSL, CTSS, CTSK recombinant proteins with >95% purity, verified by mass spec, optimal pH buffers provided. |
| Cross-species pharmacology (Cyno/Mouse) | Human, Mouse, Cyno, and Rat CTSC ortholog proteins, Endotoxin Controlled (<1 EU/µg). |
| pH-Dependent Activity Profiling | Lysosomal pH (4.5-5.0) vs Cytosolic pH (7.4) activity assays supported with pH-stable protein preparations. |
| Pro-peptide Activation State | Pre-activated Mature Tetramer provided; pro-enzyme form available for activation kinetics studies. |
| False positives / Target engagement | Validated CTSC siRNA Set included for cellular knockdown and specificity checks. |
| Assay standardization | Research-grade Anti-CTSC Antibody for binding and detection controls. |
Live CTSC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The CTSC inhibitor landscape is intensifying, driven by its critical role as the upstream activator of neutrophil serine proteases (NSPs: ELANE, PRTN3, Cathepsin G). First-generation small-molecule inhibitors (e.g., AZD7986, CC-90001) provided proof-of-concept but faced pharmacokinetic challenges and off-target toxicities. The field is now pivoting from broad anti-inflammatory indications (COPD) toward precision dermatology (periodontitis, Netherton syndrome) and rare genetic disorders (Papillon-Lefèvre Syndrome). Insmed's Brensocatib (reversible covalent inhibitor) has advanced to Phase III for non-cystic fibrosis bronchiectasis (NCFB), representing the most advanced candidate. Next-generation R&D focuses on highly selective, potent molecules with slow-off kinetics, inhaled delivery for lung diseases, and combination regimens with downstream NSP blockers. Emerging interest includes targeting neutrophil extracellular traps (NETs) in oncology and applying targeted protein degradation (PROTACs) for severe inflammation. Key to success is rigorous selectivity over cathepsin family members (B, L, S, K) and cross-species bridging for safety assessment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Covalent/Reversible) | Insmed, Boehringer Ingelheim, Novartis/AZ legacy, Voyager Therapeutics | NCFB, COPD, Periodontitis, Cystic Fibrosis, Hidradenitis Suppurativa | Enzymatic Inhibition & Selectivity Panel (Need active CTSC + Cathepsin B/L/S/K proteins) |
| Small Molecule (Reversible) | AstraZeneca, Chiesi, Academic Consortiums | Netherton Syndrome, PLS, Asthma | pH-dependent IC50 Profiling (Need active enzyme at pH 4.5-5.0) |
| Gene / Protein Therapy | Rare disease consortia, Preclinical Startups | Papillon-Lefèvre Syndrome | Functional Restoration Assays (Need unprocessed CTSC zymogen and mutant proteins) |
| Biologics (Macrocycles) | Early Discovery | Inflammatory Bowel Disease | Endosomal Escape / Lysosomal Accumulation Assays |
| Targeted Protein Degradation | Preclinical Biotech | Severe Inflammatory Disease | Cell-based Activation Assays (Need CTSC Lentivirus for stable cell lines) |
Key Mutations & Disease Relevance
CTSC loss-of-function mutations cause Papillon-Lefèvre Syndrome (PLS), an autosomal recessive disorder characterized by severe periodontitis and palmoplantar hyperkeratosis. Key mutations include R272X (rs104894210), G249S, and other premature stop codons (rs104894216) that disrupt the active tetramer formation or catalytic activity. Understanding these mutations is critical for developing gene therapy or enzyme replacement strategies. TarMart offers disease-associated mutant proteins for selectivity screening and functional restoration assays.